VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast Cancer
Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...
Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian dysfunction that drives infertility, menstrual irregularity, and long-term ...
Treatment Algorithms for Hormone Receptor–Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents ER+ breast cancers can exhibit de novo or ...
Aging is associated with progressive alterations in endocrine signalling that disrupt the regulation of energy balance and metabolic homeostasis. Changes in ...
Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification ...
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office ...
Hexarelin is a synthetic hexapeptide that emerged from late-20th-century efforts to design growth hormone–releasing peptides ...
(Beyond Pesticides, February 5, 2024) Public Comment Period Ends February 26, 2024. The U.S. Environmental Protection Agency (EPA) never completed protocol for testing pesticides that disrupt the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results